<DOC>
	<DOCNO>NCT01940848</DOCNO>
	<brief_summary>The study shall prove whether treatment irritable bowel syndrome Iberogast superior placebo .</brief_summary>
	<brief_title>Efficacy/Safety Study Confirm Iberogast 's Efficacy Rome-III Patients Irritable Bowel Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Patients either sex age &gt; 18 year Patients meet Rome III irritable bowel syndrome ( IBS ) diagnostic criterion . IBS define recurrent abdominal pain discomfort least 3 days/month last 3 month ( onset least 6 month ago ) associate two following : Improvement defecation Onset associate change frequency stool Onset associate change form ( appearance ) stool History pain intensity average bad abdominal pain past 24 hour score &gt; 30 daily measure VAS ( visual analogue scale ) screen phase Intake STW5 within last 5 year Concomitant treatment study ( include screen phase ) medication could influence gastrointestinal function Regular intake nonsteroidal antiphlogistic drug incl . COX2inhibitors ( exception : acetylsalicylic acid cardiovascular prevention 100 mg daily ) Patients know hypersensitivity component trial drug History eat disorder Patients history diseases abdominal symptom resemble IBS Presence acute chronic gastrointestinal disorder History abdominal surgery ( cholecystectomy appendectomy tolerate perform least one year previously ) Known intolerance azo dye E 110 E 151</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Iberogast</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>